To potentially overcome such resistance and achieve enhanced patient responses, our investigations facilitate exploration on PD-1/PD-L1 inhibitors as an add-on approach to conventional CLL therapies as a groundwork for subsequent experimental investigations. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.